Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125909961 | 12590996 | 1 | I | 20160427 | 20160511 | 20160726 | 20160726 | PER | US-UNITED THERAPEUTICS-UNT-2016-007741 | UNITED THERAPEUTICS | 50.00 | YR | F | Y | 0.00000 | 20160726 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125909961 | 12590996 | 1 | PS | ORENITRAM | TREPROSTINIL | 1 | Oral | 3.5 MG, TID | 203496 | 3.5 | MG | TABLET | TID | ||||||
| 125909961 | 12590996 | 2 | SS | AMBRISENTAN | AMBRISENTAN | 1 | Unknown | 5 MG, QD | U | U | SBFS | 0 | 5 | MG | TABLET | QD | |||
| 125909961 | 12590996 | 3 | SS | ADCIRCA | TADALAFIL | 1 | Unknown | U | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125909961 | 12590996 | 1 | Pulmonary arterial hypertension |
| 125909961 | 12590996 | 2 | Pulmonary hypertension |
| 125909961 | 12590996 | 3 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125909961 | 12590996 | Cough | |
| 125909961 | 12590996 | Nasopharyngitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |